
    
      A randomized, double-blind, placebo-controlled clinical trial in 18 men aged between 30 and
      50 years with obesity (BMI 30-39.9) according to the World Health Organization (WHO) criteria
      without treatment.

      They will be assigned randomly in two groups of 9 patients, each to receive 5 mg of tadalafil
      or placebo every day at night during 28 days.

      There will be evaluated Insulin secretion, both first phase of insulin secretion by Stumvoll
      Inex as well as Total Insulin Secretion by Area Under the Curve of glucose and insulin and
      Insulinogenic Index, and Insulin sensitivity by Matsuda index.

      Waist circumference, glucose and insulin levels, lipid profile and blood pressure are going
      to be load will be evaluated before and after intervention in both groups.

      Statistical analysis will be presented through measures of central tendency and dispersion,
      average and deviation standard for quantitative variables; frequencies and percentages for
      variable qualitative. Qualitative variables will be analyzed by X2, will be used for
      differences inter-group Mann-Whitney U Test and Wilcoxon Test for the within-groups
      differences. Will be considered statistical significance p â‰¤0.05.

      This protocol was approved by a local Ethics Committee and written informed consent will be
      obtained from all volunteers.
    
  